文献速递胸部肿瘤放疗姑息放疗与转移瘤

不可治愈非小细胞肺癌老年医保患者中的姑息性放疗与分次方案

Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer.
PubMed 文献 · Adv Radiat Oncol · 2018-04-23

该回顾性分析利用美国监测、流行病学和最终结果(SEER)医保数据,纳入2004至2011年确诊的不可治愈非小细胞肺癌(NSCLC)患者55,258例。38%(21,053例)在确诊后第一年内接受姑息性放疗,其中56%(11,717例)接受超过10次分次。游离放疗中心较医院内中心更常使用超过10次分次(58% vs 43%;OR:1.7;P < .01)。

要点

  • 55,258例不可治愈NSCLC患者中38%在确诊后第一年接受姑息性放疗,其中56%接受超过10次分次。
  • 化疗使用与接受姑息性放疗(OR:3.6;P < .01)及超过10次分次(OR:1.7;P < .01)相关。
  • 游离中心较医院内中心更常使用超过10次分次(58% vs 43%;OR:1.7;P < .01)。

核心结论

  • 超过三分之一的不可治愈肺癌患者接受姑息性放疗,其中56%接受超过10次分次。
  • 放疗使用因地区和患者特征而异,游离放疗中心治疗的患者更可能接受超过10次分次。
  • 作者认为,进一步研究影响治疗决策的因素(包括潜在经济激励)可能有助于姑息性放疗的高价值与策略性利用。

研究设计与样本

  • 回顾性分析美国监测、流行病学和最终结果(SEER)医保数据。
  • 纳入2004至2011年确诊的不可治愈NSCLC患者(美国癌症联合委员会第6版分期IIIB期伴恶性积液或IV期)。
  • 采用单因素和多因素逻辑回归分析接受姑息性放疗及首次放疗疗程中使用超过10次分次的相关因素。
  • 在放疗患者中,根据放疗实施索赔地点收集游离中心与医院内中心信息。

主要发现

  • 55,258例不可治愈NSCLC患者中,38%(21,053例)在确诊后第一年内接受姑息性放疗。
  • 接受放疗的患者中,56%(11,717例)接受超过10次分次。
  • 多因素分析中,与更多放疗使用相关的因素包括较年轻年龄组(总体P < .01)、较低改良Charlson合并症评分(总体P < .01)、女性(OR:1.1;P < .01)、已婚状态(OR:1.1;P < .01)和化疗使用(OR:3.6;P < .01)。
  • 超过10次分次的预测因素为化疗使用(OR:1.7;P < .01)和在游离中心 versus 医院内中心治疗(58% vs 43%;OR:1.7;P < .01)。

关键数值与推荐

  • 不可治愈定义:美国癌症联合委员会第6版分期IIIB期伴恶性积液或IV期。
  • 接受姑息性放疗:确诊后第一年内38%(21,053/55,258例)。
  • 超过10次分次:接受放疗患者中56%(11,717例)。
  • 化疗使用与接受放疗的OR:3.6(P < .01);化疗使用与超过10次分次的OR:1.7(P < .01)。
  • 游离中心 vs 医院内中心接受超过10次分次:58% vs 43%(OR:1.7;P < .01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Palliative radiation therapy (RT) can improve quality of life but also incurs time and financial costs. The aim of this study was to evaluate factors associated with use and intensity of palliative RT for incurable non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This was a retrospective analysis of Medicare's Surveillance, Epidemiology and End Results data. We identified patients who were diagnosed with incurable (American Joint Committee on Cancer 6th edition stage IIIB with malignant effusion or stage IV) NSCLC between 2004 and 2011. Univariable and multivariable logistic regressions were used to identify factors associated with the receipt of palliative RT and the use of >10 fractions during the first course of radiation. Among patients who were treated with radiation, freestanding versus hospital-based center information was collected on the basis of the location of the RT delivery claim. RESULTS: Among 55,258 patients with incurable NSCLC, 38% (21,053 patients) received palliative RT during the first year after diagnosis. Among patients who received RT, 56% (11,717 patients) received >10 fractions. On multivariable analysis, factors associated with greater RT use included younger age group (overall P < .01), lower modified Charlson comorbidity score (overall P < .01), female sex (odds ratio [OR]: 1.1; P < .01), marital status (OR: 1.1; P < .01), and chemotherapy use (OR: 3.6; P < .01). Predictors for >10 fractions were chemotherapy use (OR: 1.7; P < .01) and treatment at a freestanding versus hospital-based facility (58% vs 43%; OR: 1.7; P < .01). CONCLUSIONS: More than a third of patients diagnosed with incurable lung cancer receive palliative RT and 56% received >10 fractions. The use of RT varied by region and patient characteristics, and patients treated at freestanding RT centers were more likely to receive >10 fractions. Further research into factors that influence treatment decisions including potential financial incentives may contribute to the high value and strategic utilization of palliative RT.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lam MB, Li L, Cronin A, et al. Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer. Adv Radiat Oncol. 2018. PMID: 30202806. doi:10.1016/j.adro.2018.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。